Clinical efficacy of remdesivir for COVID-19 in children: A propensity-score-matched analysis

被引：3

作者：

Shoji, Kensuke ^{[1
,6
]}

Asai, Yusuke ^{[2
,3
]}

Akiyama, Takayuki ^{[2
]}

Tsuzuki, Shinya ^{[2
,3
,4
]}

Matsunaga, Nobuaki ^{[2
]}

Suzuki, Setsuko

Iwamoto, Noriko ^{[3
]}

Funaki, Takanori ^{[1
]}

Miyairi, Isao ^{[1
,5
]}

Ohmagari, Norio ^{[2
,3
]}

机构：

[1] Natl Ctr Child Hlth & Dev, Dept Med Subspecialties, Div Infect Dis, Tokyo, Japan

[2] Natl Ctr Global Hlth & Med, AMR Clin Reference Ctr, Tokyo, Japan

[3] Natl Ctr Global Hlth & Med, Dis Control & Prevent Ctr, Dept Infect Dis, Tokyo, Japan

[4] Univ Antwerp, Fac Med & Hlth Sci, Antwerp, Belgium

[5] Hamamatsu Univ Sch Med, Dept Pediat, Hamamatsu, Shizuoka, Japan

[6] Natl Ctr Child Hlth & Dev, Dept Med Subspecialties, Div Infect Dis, 2-10-1 Okura,Setagaya Ku, Tokyo, Japan

来源：

JOURNAL OF INFECTION AND CHEMOTHERAPY | 2023年 / 29卷 / 09期

关键词：

Remdesivir; Children; Coronavirus disease 2019; Severe acute respiratory syndrome coronavirus; Defervescence;

D O I：

10.1016/j.jiac.2023.06.006

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Clinical efficacy of remdesivir in children with COVID-19 is unclear. This propensity-score-matched retrospective cohort study of children with COVID-19 showed that the rate of patients achieving defervescence on Day 4 was higher in the remdesivir group than in the non-remdesivir group, but was not statistically different (86.7% vs 73.3%, P = 0.333).

引用

页码：930 / 933

页数：4

共 50 条

[41] Use of Remdesivir in Myasthenia gravis and COVID-19
Peters, Bradley J.
Rabinstein, Alejandro A.
DuBrock, Hilary M.
PHARMACOTHERAPY, 2021, 41 (06): : 546 - 550
[42] Remdesivir for the Treatment of COVID-19: A Narrative Review
Godwin, Patrick O.
Polsonetti, Bryan
Caron, Michael F.
Oppelt, Thomas F.
INFECTIOUS DISEASES AND THERAPY, 2024, 13 (01) : 1 - 19
[43] Remdesivir: treatment of COVID-19 in special populations
Molaei, Emad
Molaei, Ali
Hayes, A. Wallace
Karimi, Gholamreza
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (06) : 3829 - 3855
[44] Remdesivir for COVID-19: Why Not Dose Higher?
Yan, Victoria C.
Mueller, Florian L.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (04)
[45] Remdesivir for the Treatment of COVID-19: A Narrative Review
Patrick O. Godwin
Bryan Polsonetti
Michael F. Caron
Thomas F. Oppelt
Infectious Diseases and Therapy, 2024, 13 : 1 - 19
[46] Remdesivir in Severe Cases of COVID-19 Infection
Boretti, Alberto
CURRENT ORGANOCATALYSIS, 2024, 11 (04) : 273 - 278
[47] Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis
Lee, Todd C.
Murthy, Srinivas
Del Corpo, Olivier
Senecal, Julien
Butler-Laporte, Guillaume
Sohani, Zahra N.
Brophy, James M.
McDonald, Emily G.
CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (09) : 1203 - 1210
[48] Clinical Characteristics of Children with COVID-19
Ho, Carmen Lok Tung
Oligbu, Peter
Ojubolamo, Olakunle
Pervaiz, Muhammad
Oligbu, Godwin
AIMS PUBLIC HEALTH, 2020, 7 (02): : 258 - 273
[49] Effect of interferon-α on COVID-19 in-hospital mortality: a large-scale propensity score-matched study
Mohamad Amin Pourhoseingholi
Amirreza Rafiei Javazm
Naghmeh Asadimanesh
Fatemeh Shojaeian
Mehdi Azizmohammad Looha
Seyed Amir Ahmad Safavi-Naini
Benyamin Mohammadzadeh
Parnian Jamshidi
Fatemeh Gholampoor
Omid Yazdani
Nadia Zameni
Zahra Azizan
Amirhossein Sahebkar
European Cytokine Network, 2023, 34 : 10 - 19
[50] Remdesivir in a pregnant patient with COVID-19 pneumonia
Dande, Ranadheer
Qureshi, Anum
Persaud, Kia
Puri, Chahat
Zulfiqar, Sajida
Awasthi, Shankar
JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES, 2021, 11 (01): : 103 - 106

← 1 2 3 4 5 →